Evidence map›Paper›PMID 38429807›Full record

ArticleMalaria journal2024

Progress towards malaria elimination in the Greater Mekong Subregion: perspectives from the World Health Organization.

Giulia Manzoni, Rady Try, Jean Olivier Guintran, Céline Christiansen-Jucht, Elodie Jacoby, Siv Sovannaroth, Zaixing Zhang, Vilasack Banouvong, Matthew Scott Shortus, Rita Reyburn and 15 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
27.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Spatiotemporal Dynamics ofChina CDC weekly · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Temporal trends inmedRxiv : the preprint server for health sciences · 2026
    Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 8 countries.

Giulia ManzoniWHO Mekong Malaria Elimination Programme, Phnom Penh, Cambodia. giuliamanzoni88@yahoo.it.
Rady TryWHO Mekong Malaria Elimination Programme, Phnom Penh, Cambodia.
Jean Olivier GuintranWorld Health Organization Country Office, Phnom Penh, Cambodia.
Céline Christiansen-JuchtWHO Mekong Malaria Elimination Programme, Phnom Penh, Cambodia.
Elodie JacobyWHO Mekong Malaria Elimination Programme, Phnom Penh, Cambodia.
Siv SovannarothNational Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.
Zaixing ZhangWorld Health Organization Country Office, Phnom Penh, Cambodia.
Vilasack BanouvongCentre for Malariology, Parasitology and Entomology, Vientiane, Lao PDR.
Matthew Scott ShortusWorld Health Organization Country Office, Vientiane, Lao PDR.
Rita ReyburnWorld Health Organization Country Office, Vientiane, Lao PDR.
Chitsavang ChanthavisoukWorld Health Organization Country Office, Vientiane, Lao PDR.
Nay Yi Yi LinnNational Malaria Control Programme, Nay Pyi Taw, Myanmar.
Badri ThapaWorld Health Organization Country Office, Yangon, Myanmar.
San Kyawt KhineWorld Health Organization Country Office, Yangon, Myanmar.
Prayuth SudathipDivision of Vector Borne Diseases, Department of Disease Control, Bangkok, Thailand.
Deyer GopinathWorld Health Organization Country Office, Bangkok, Thailand.
Nguyen Quang ThieuNational Institute of Malariology, Parasitology and Entomology, Hanoi, Viet Nam.
Mya Sapal NgonWorld Health Organization, Hanoi, Viet Nam.
Dai Tran CongWorld Health Organization, Hanoi, Viet Nam.
Liu HuiYunnan Institute of Parasitic Diseases, Yunnan, China.
James KelleyWorld Health Organization, Regional Office for the Western Pacific, Manila, Philippines.
Neena Nee Kesar ValechaWorld Health Organization, Regional Office for South-East Asia, New Delhi, India.
Maria Dorina BustosWorld Health Organization, Regional Office for South-East Asia, New Delhi, India.
Charlotte RasmussenGlobal Malaria Programme, World Health Organization, Geneva, Switzerland.
Luciano TuseoWHO Mekong Malaria Elimination Programme, Phnom Penh, Cambodia.
Cambodia National Malaria Center · KHWorld Health Organization - Pakistan · PKNational Institute of Malariology, Parasitology and Entomology · VNWorld Health Organization Regional Office for South-East Asia · INWorld Health Organization · CHWorld Health Organization Regional Office for the Western Pacific · PHYunnan Institute of Parasitic Diseases · CN

Funding

World Health Organization 001
6 · The paper itself

Abstract

Malaria remains a global health challenge, disproportionately affecting vulnerable communities. Despite substantial progress, the emergence of anti-malarial drug resistance poses a constant threat. The Greater Mekong Subregion (GMS), which includes Cambodia, China's Yunnan province, Lao People's Democratic Republic, Myanmar, Thailand, and Viet Nam has been the epicentre for the emergence of resistance to successive generations of anti-malarial therapies. From the perspective of the World Health Organization (WHO), this article considers the collaborative efforts in the GMS, to contain Plasmodium falciparum artemisinin partial resistance and multi-drug resistance and to advance malaria elimination. The emergence of artemisinin partial resistance in the GMS necessitated urgent action and regional collaboration resulting in the Strategy for Malaria Elimination in the Greater Mekong Subregion (2015-2030), advocating for accelerated malaria elimination interventions tailored to country needs, co-ordinated and supported by the WHO Mekong malaria elimination programme. The strategy has delivered substantial reductions in malaria across all GMS countries, with a 77% reduction in malaria cases and a 97% reduction in malaria deaths across the GMS between 2012 and 2022. Notably, China was certified malaria-free by WHO in 2021. Countries' ownership and accountability have been pivotal, with each GMS country outlining its priorities in strategic and annual work plans. The development of strong networks for anti-malarial drug resistance surveillance and epidemiological surveillance was essential. Harmonization of policies and guidelines enhanced collaboration, ensuring that activities were driven by evidence. Challenges persist, particularly in Myanmar, where security concerns have limited recent progress, though an intensification and acceleration plan aims to regain momentum. Barriers to implementation can slow progress and continuing innovation is needed. Accessing mobile and migrant populations is key to addressing remaining transmission foci, requiring effective cross-border collaboration. In conclusion, the GMS has made significant progress towards malaria elimination, particularly in the east where several countries are close to P. falciparum elimination. New and persisting challenges require sustained efforts and continued close collaboration. The GMS countries have repeatedly risen to every obstacle presented, and now is the time to re-double efforts and achieve the 2030 goal of malaria elimination for the region.

Indexed as

AntimalarialsArtemisininsMalariaMalaria, FalciparumAsia, SoutheasternHumansWorld Health OrganizationAntimalarialsartemisininArtemisininsAntimalarial drug resistanceEliminationGreater Mekong SubregionMalariaWorld Health Organization

Identifiers

PMID38429807
PMCPMC10908136
OpenAlexW4392388551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.